Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Peer Schatz Board Appointments at Siemens, Centogene; More

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.


Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.


Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.


For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.